OMALIZUMAB and COUGH

Overview

COUGH is the #7 most commonly reported adverse reaction for OMALIZUMAB, manufactured by Genentech, Inc.. There are 6,768 FDA adverse event reports linking OMALIZUMAB to COUGH. This represents approximately 2.7% of all 248,573 adverse event reports for this drug.

OMALIZUMAB has an overall safety score of 78 out of 100. Patients taking OMALIZUMAB who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is a less commonly reported adverse event for OMALIZUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of OMALIZUMAB

In addition to cough, the following adverse reactions have been reported for OMALIZUMAB:

• ASTHMA — 11,600 reports
• URTICARIA — 10,326 reports
• NO ADVERSE EVENT — 10,204 reports
• OFF LABEL USE — 9,929 reports
• DYSPNOEA — 9,875 reports
• DRUG INEFFECTIVE — 7,780 reports
• PRURITUS — 5,943 reports
• FATIGUE — 5,824 reports
• MALAISE — 5,429 reports
• WHEEZING — 5,239 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does OMALIZUMAB cause COUGH?

COUGH has been reported as an adverse event in 6,768 FDA reports for OMALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with OMALIZUMAB?

COUGH accounts for approximately 2.7% of all adverse event reports for OMALIZUMAB, making it a notable side effect.

What should I do if I experience COUGH while taking OMALIZUMAB?

If you experience cough while taking OMALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages